Ilkka Ilonen

Prof. Dr. Ilkka Ilonen

1. Department of General and Oesophageal Surgery, Lung and Heart Centre, Helsinki University Hospital, Helsinki, Finland. 2. Department of Surgery, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2018 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
TJTommi Järvinen
Tommi Järvinen
IIIlkka Ilonen
Ilkka Ilonen
JKJuha Kauppi
Juha Kauppi
JSJarmo Salo
Jarmo Salo
JRJari Räsänen
Jari Räsänen
Nutritional deficits, cachexia, and sarcopenia are extremely common in esophageal cancer. The aim of this article was to assess the effect of loss of skeletal muscle mass during neoadjuvant treatment on the prognosis of esophageal cancer patients. Esophageal cancer patients (N = 115) undergoing neoadjuvant therapy and surgery between 2010 and 2014 were identified from our surgery database and retrospectively analyzed. Computed tomography imaging of the total cross-sectional muscle tissue measured at the third lumbar level defined the skeletal muscle index, which defined sarcopenia (SMI < 52.4 cm2/m2 for men and < 38.5 cm2/m2 for women). Images were collected before and after neoadjuvant treatments. Sarcopenia in preoperative imaging was prevalent in 92 patients (80%). Median overall survival was 900 days (interquartile range 334–1447) with no difference between sarcopenic (median = 900) and non-sarcopenic (median = 914) groups (p = 0.872). Complication rates did not differ (26.1% vs 32.6%, p = 0.725). A 2.98% decrease in skeletal muscle index during neoadjuvant treatment correlated with poor 2-year survival (log-rank p = 0.04). Loss of skeletal muscle tissue during neoadjuvant treatment correlates with worse overall survival.

2 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BABassel Alsaed
Bassel Alsaed
LLLinh Lin
Linh Lin
JSJieun Son
Jieun Son
JLJiaqi Li
Jiaqi Li
JSJohannes Smolander
Johannes Smolander
HHHeidi M. Haikala
Heidi M. Haikala
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are commonly used to treat non-small cell lung cancers with EGFR mutations, but drug resistance often emerges. Intratumor heterogeneity is a known cause of targeted therapy resistance and is considered a major factor in treatment failure. This study identifies clones of EGFR-mutant non-small cell lung tumors expressing low levels of both wild-type and mutant EGFR protein. These EGFR-low cells are intrinsically more tolerant to EGFR inhibitors, more invasive, and exhibit an epithelial-to-mesenchymal-like phenotype compared to their EGFR-high counterparts. The EGFR-low cells secrete Transforming growth factor beta (TGFβ) family cytokines, leading to increased recruitment of cancer-associated fibroblasts and immune suppression, thus contributing to the drug-tolerant tumor microenvironment. Notably, pharmacological induction of EGFR using epigenetic inhibitors sensitizes the resistant cells to EGFR inhibition. These findings suggest that intrinsic drug resistance can be prevented or reversed using combination therapies.

1 January 2015 in Clinical Lung Cancer
Verified
Journal Article
Closed access
VRVille Rauma
Ville Rauma
HSHarri Sintonen
Harri Sintonen
JRJari Räsänen
Jari Räsänen
JSJarmo A. Salo
Jarmo A. Salo
IIIlkka Ilonen
Ilkka Ilonen

11 February 2011 in Acta Oncologica
Verified
Journal Article
Closed access
PDF file
IIIlkka Ilonen
Ilkka Ilonen
JRJari Räsänen
Jari Räsänen
AKAija Knuuttila
Aija Knuuttila
JSJarmo A. Salo
Jarmo A. Salo
ESEero I. Sihvo
Eero I. Sihvo
Background. Patients undergoing surgery for non-small cell lung cancer (NSCLC) are often elderly with co-morbid conditions and decreased performance status. Thus, the morbidity of lung resection via thoracotomy may be unacceptable for some patients. This is the reason why video-assisted thoracoscopic surgery (VATS) instead of open thoracotomy has gained more use and acceptance, especially in patients with stage I disease. The aim of this study was to evaluate the difference between VATS and open thoracotomy in treatment outcomes of stage I NSCLC patients. Methods. A total of 328 stage I NSCLC patients underwent lobectomy, bilobectomy or segmentectomy between January 2000 and February 2010. VATS was implemented in 116 patients, of which 16 were converted to thoracotomy. Muscle-sparing anterolateral thoracotomy was performed in 212. Propensity-matched groups were analyzed based on preoperative variables and stage. Results. VATS was associated with lower postoperative morbidity in both overall (p = 0.020) and propensity-matched analysis (p = 0.026) and shorter hospitalization (both p < 0.001). Patients selected for VATS were older (p = 0.001) with a significantly higher Charlson comorbidity index (p = 0.007) and poorer diffusion capacity (p < 0.001). The conversion rate was 14%. Between the two groups, no significant difference was observable in two-year overall and progression-free survival. Conclusions. Despite the VATS lobectomy and segmentectomy patients’ being older, with more comorbid condition and poorer pulmonary function, the incidence of major complications was lower and hospitalization shorter than for open thoracotomy patients. For stage I NSCLC, VATS should be considered the primary surgical approach.

1 January 2020 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
EREric M. Robinson
Eric M. Robinson
IIIlkka Ilonen
Ilkka Ilonen
KTKay See Tan
Kay See Tan
APAndrew J. Plodkowski
Andrew J. Plodkowski
MBMatthew Bott
Matthew Bott
JHJames Huang
James Huang

1 March 2005 in Transplantation Proceedings
Verified
Journal Article
Closed access
HIH. Isoniemi
H. Isoniemi
AKA.-M. Koivusalo
A.-M. Koivusalo
HRH. Repo
H. Repo
IIIlkka Ilonen
Ilkka Ilonen
KHK. Höckerstedt
K. Höckerstedt